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Abstract
Objectives To detail the greatest areas of unmet
scientific and clinical needs in rheumatology.
Methods The 21st annual international Advances in
Targeted Therapies meeting brought together more than
100 leading basic scientists and clinical researchers in
rheumatology, immunology, epidemiology, molecular
biology and other specialties. During the meeting,
breakout sessions were convened, consisting of 5
disease-specific groups with 20–30 experts assigned
to each group based on expertise. Specific groups
included: rheumatoid arthritis, psoriatic arthritis, axial
spondyloarthritis, systemic lupus erythematosus and
other systemic autoimmune rheumatic diseases. In each
group, experts were asked to identify unmet clinical
and translational research needs in general and then to
prioritise and detail the most important specific needs
within each disease area.
Results Overarching themes across all disease states
included the need to innovate clinical trial design with
emphasis on studying patients with refractory disease,
the development of trials that take into account disease
endotypes and patients with overlapping inflammatory
diseases, the need to better understand the prevalence
and incidence of inflammatory diseases in developing
regions of the world and ultimately to develop therapies
that can cure inflammatory autoimmune diseases.
Conclusions Unmet needs for new therapies and trial
designs, particularly for those with treatment refractory
disease, remain a top priority in rheumatology.
Background
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The Advances in Targeted Therapies meeting
(ATT) has met annually for 21 years, bringing
together clinical scientists and immunology and
molecular biology experts from around the world.
The meeting focuses on clinical and translational
research, in immune-
mediated inflammatory
diseases (IMIDs) and stimulates collaboration
between basic scientists and clinicians. The meeting’s objective is to update participants regarding
the latest insights regarding disease mechanism(s)
and pathophysiology and recent developments
with both existing and novel targeted therapies
in the field of IMIDs with a focus on rheumatological diseases. Previously, a consensus document
describing the recommended use of targeted therapies within rheumatology was produced from this
meeting.1 However, with the expanse of targeted
therapies and the recent clinical recommendations

Key messages
What is already known about this subject?

►► Key unmet needs in field of rheumatology

clinical and basic science research have been
highlighted previously, but vary over time as the
field progresses.

What does this study add?

►► The Advances in Targeted Therapies meeting

(ATT) focuses on clinical and translational
research, in immune-mediated inflammatory
diseases (IMIDs) and stimulates collaboration
between basic scientists and clinicians. With
the 2019 meeting, we reviewed, updated and
prioritised the unmet research needs in the field
►► This effort highlighted several overarching
themes: the need to innovate clinical trial
design with emphasis on studying patients
with refractory disease, the development of
trials that take into account disease endotypes
and patients with overlapping inflammatory
diseases, and the need to better understand
the prevalence and incidence of inflammatory
diseases in developing regions of the world.
How might this impact on clinical practice?

►► The prioritisation and highlighting of research

needs, particularly in aspects of clinical trial
design, will ultimately result in improvements in
therapy and potentially the better targeting of
therapies toward patients with specific disease
sub-types.

published from both American College of Rheumatology and the European Union League Against
Rheumatism,2–4 a document covering all targeted
therapies across all disease indications became too
complex and voluminous as a single manuscript.
Accordingly, the annual meeting’s output was modified to discuss key unmet needs within the field,
consistent with the meeting’s underlying objective
of promoting innovation and collaboration.5 With
the 2019 meeting, we conducted a similar process
to review and update these unmet needs, but in this
case, prioritise and highlight the most important
needs in the field.
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Methods

We assigned conference participants to disease-specific breakout
groups which included psoriatic arthritis (PsA), rheumatoid
arthritis (RA), axial spondyloarthritis (axSpA), systemic lupus
erythematous (SLE) and other systemic autoimmune rheumatic
diseases including vasculitis. Experts in each group were tasked
with identifying unmet needs in three categorical areas: clinical
care, clinical science and therapeutic development and basic/
translational science. A ‘facilitator’ and ‘rapporteur’ led each
group’s discussion and summarised their results, and the groups
were asked to highlight notable progress made towards previously identified needs as well as identify new areas of need. This
year, each group was asked to then prioritise their discussion
and detail the top several needs within each disease-specific area.

Results
Rheumatoid arthritis

There was broad agreement that management of patients with
RA who are refractory to available treatments (‘refractory’ or
‘treatment resistant’ RA) is arguably the greatest unmet need
in RA (at least in the developed world). However, a careful
clinical definition of the refractory state is needed, so that we
are not confounding true treatment-
refractory disease with
patients with RA who are undertreated, non-adherent to treatment or who have comorbid fibromyalgia or other sources of
non-inflammatory pain. Once a clinical definition of ‘refractory’ RA is achieved, a molecular definition of the refractory
state should follow and should be differentiated from molecular definitions of early RA, established RA, RA in flare and RA
in remission. Single cell analysis of synovial and/or circulating
cells (including gene expression) may enable us to phenotype
RA into subgroups or states of disease.6 Molecular characteristics at single cell level should be compared with whole synovial
tissue molecular profiling with the aim of identifying peripheral blood surrogates of tissue pathology (liquid biopsy) and
treatment response. The definitions of molecular subgroups
could eventually lead to a personalised approach to treatment.
For example, data generated may suggest that a combination
or sequence of biologics may be efficacious in some individuals. Alternatively, molecular subgrouping may identify novel
targets proximal in the disease process—that is, in the early
adaptive immune response—that could be targeted for drug
development and clinical trials.
Importantly, patients who have received multiple biologics/
small molecules should not be excluded from clinical trials since
they have the greatest unmet need. Novel targeted therapies
should be studied in refractory patients, as should novel combinations or sequences of existing therapies, similar to the way
oncologists use checkpoint inhibitors. In particular, we should
carefully move forward with combination therapy studies in
refractory patients, with a commitment to resolving issues of
cost, safety (eg, infection and malignancy) and the reluctance of
manufacturers to combine each other’s agents. Efforts to identify optimal dosing and levels of our currently available therapies, as a single treatment or in combination, are also essential to
optimise treatment of refractory patients. Finally, it is important
to recognise that despite many successful therapies for RA, less
than half of patients with RA are in remission, 10%–15% are
refractory, and there is still no cure for this disease.7–9 Continued
commitment on the part of our funding agencies, pharmaceutical partners and scientific investigators is essential to advance
research and discovery efforts to understanding the heterogeneity of RA pathogenesis and effective sustainable treatments.

Psoriatic arthritis
In the last few years, there have been an increasing number of
medications with different mechanisms of action which have
shown benefit in PsA in randomised clinical trials and have been
approved by regulatory agencies, including an IL12-23 inhibitor (ustekinumab), two IL-
17A inhibitors (secukinumab and
ixekizumab), an oral PDE4 inhibitor (apremilast), an oral JAK
inhibitor (tofacitinib) and abatacept.10 11 While very gratifying,
the homogeneity imposed by clinical trial design may exclude
important patient subgroups. For example, the great majority
of patients have polyarticular involvement (entry criteria:
≥3–5 inflamed joints) with few studies examining oligoarticular disease (<5 inflamed joints); thus, the common oligoarticular PsA represents an unmet need in PsA trials. Although the
varied clinical domains of PsA, (eg, enthesitis, dactylitis, spondylitis) can show response to treatment, only a subset of patients
demonstrate these domains and thus the measured response
may not achieve statistical significance if the subset is too small.
Furthermore, a domain such as PsA spondylitis, with symptomatic inflammatory back pain in about 15% and asymptomatic
sacroiliitis in about 30% of patients,12 is not measured by the
standards of axSpA trials, including centrally read MRI. The
best way to measure oligoarticular disease in trials remains an
unmet need, and since the oligoarticular phenotype is a common
presentation in clinical practice, we are not able to entirely accurately extrapolate results from trials to clinical practice. For
treatment of the spondylitis component of PsA, we rely on data
from axSpA trials, which also may not be accurately extrapolatable. Trials of the IL-12/23 inhibitor ustekinumab and the IL-23
inhibitor risankizumab have failed in ankylosing spondylitis.13
Even though these agents have demonstrated benefit and been
approved for PsA, their ability to benefit the spinal component
of PsA remains unproven and needs to be tested.
Phase IIIB or IV trials which specifically enrich the patient
population for the domain or subtype in question are needed.
Enrolment criteria could require oligoarticular disease or spondylitis or enthesitis for example, although measurement techniques for these disease aspects still need to be developed. Specific
ultrasound or MRI (eg, axial clinical and imaging measures
for a spondylitis-specific trial, entheseal-specific measures and
imaging for an enthesitis trial) are needed. It is not clear how
the results of these trials could be incorporated into regulatory
labelling for the medication, but these would provide important
clinical data helpful for clinical decision-making.
A second area of major unmet need in PsA is management
of the therapy refractory patients who have ‘tried everything’.
Emergence of new approved therapies will partially address this
need, as would rational ‘combination’ studies. Clinicians are
more frequently trying unapproved combination approaches, for
example combining a biological medication (TNFi, IL-17i and
so on) with an oral agent such as a PDE4i or JAKi. Combination
therapy trials are urgently needed, although the safety of such
combination approaches is unknown, particularly with regard
to infection, where a greater risk has been suggested in some
combination trials for RA.14
A third major area of unmet need is better understanding
of, and accounting for, the role of central sensitisation (CSS)
(chronic widespread pain, fibromyalgia) in amplifying symptom
severity. Recent studies have demonstrated that 15%–40% of
patients with PsA and other rheumatic, chronic pain and inflammatory conditions may have concomitant CSS. When CSS is
concomitantly present with PsA, disease activity measures which
include patient-
reported outcomes, (eg, pain, patient global)
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are nearly twice as severe when compared with a similar PsA
cohort that lacks CSS.15–17 Patients with PsA with concomitant
CSS are less likely or unable to achieve targets of treatment such
as minimal disease activity,16–18 Højgaard et al demonstrated in
this population lack of correlation between tender entheseal
examination and evidence of objective evidence of inflammation by ultrasound.17 18 While patients with CSS are historically excluded from PsA trials, it is difficult to exclude all such
patients. Several measures have been developed to ascertain the
presence of CSS/fibromyalgia;17 however, there remains a need
for more objective biomarkers which are more feasible to use in
clinical and trial settings. In this respect it is noteworthy, that
the treat-to-target recommendations for PsA explicitly state that
‘The choice of the target and of the disease activity measure
should take comorbidities, patient factors and drug-related risks
into account’ (recommendation #8);19 this simply means that
an index developed for measuring disease activity in PsA should
not be used to score a comorbid condition, alternatives will then
have to be used. Similarly, a prerequisite for application of classification criteria for RA is that a patient has no other diagnosis,
such as SLE.20

Ankylosing spondyloarthritis

In 2018, the spondyloarthritis discussion group identified a
variety of unmet needs which included: understanding the relationship of peripheral disease to axial disease; early recognition
and diagnosis of disease; understanding the causes/relationship
of extra-articular disease including bowel and eye disease to the
joint disease; improved imaging technologies and interpretation;
development of biomarkers for prognosis and choice of therapy;
a wider choice of biological therapies; an ability to improve
prognosis (disease modifying treatment); direct comparison
among TNF inhibitors with regard to efficacy and safety; more
frequent disease remission; improved referral to a rheumatologist and international collaboration.21
Although this list is comprehensive, additional themes were
identified as most important. First, the need to better understand
the microbiome is paramount. While it is highly likely that the
gut microbiome is contributing to the disease, we do not know
which bacteria are most important, which portion of the bowel
is most important, the mechanism by which the bacteria affect
the disease, the role of non-gut microbiota, the role of non-
bacterial microbiota or how best to therapeutically alter the gut
microbiome as by diet of faecal transplant. Second, the failure
to establish IL-23 as an effective therapeutic target in ankylosing
spondylitis means that we need to understand more completely
the IL-23-IL-17 axis and the role of IL-23 and additional cytokines in the molecular pathogenesis of this disease.22–25 This
effort should include a more complete understanding of the
relative function of all members of the IL-17 family, including
IL-17F and further understanding of which cells secrete IL-17
and why this does not seem to be under the control of IL-23 in
this disease.26 We also need a better understanding as to how
the disease results in both new bone formation and osteoporosis.27 Unfortunately, it still takes many years in daily clinical
practice before a diagnosis of axial SpA is made.28 29 Therefore,
approaches for referral in primary care and for early diagnosis
have to be further developed and implemented. Last, there is still
further need for international agreement (and implementation)
on nomenclature of axial SpA.30 31

Systemic lupus erythematosus

Recent failures of clinical trials in SLE demonstrate weaknesses
in current methodology and opportunities for improvement in
90

multiple areas.32–37 The theme of improving clinical trial design,
including limiting disease heterogeneity, was prioritised in
discussion. Specifically, learning from already available data was
deemed essential. Analysis of the primary data from completed
clinical trials, especially combining those from several studies,
can provide essential insights that can guide decisions for new
studies.38 Comparing the characteristics of the patients that
participated in the trials with the data that are available from
independent patient registries could be helpful to identify a bias
in trial patient selection that might help to better understand
trial outcomes. Issues that may confound clinical trials, including
which patients should, or perhaps more importantly, should not
be enrolled can be addressed using this type of analysis. Furthermore, evaluation of potential outcome measures39–41 and the
effects of background therapy or comorbidities that impact relative response to the study drug can be determined. This type
of analysis has limitations related to which patients were actually enrolled in the trials to be analysed. Here, an appropriate
serological test to identify autoantibody positive patients based
on sound technology is paramount.42 43 Other datasets that may
inform clinical trial design in different ways include patient
registry studies, electronic medical record cohorts and administrative datasets, although issues of data quality, completeness
and timeliness must be considered.44–47 Lupus trials are typically
conducted with background therapy32 35 48 49 and there is little
agreement on how this should be controlled during the conduct
and analysis of a study.43 In fact, the ‘standard of care’ medication in SLE in general has not been defined.43 50
There are important ongoing issues surrounding the
disease heterogeneity that also affect clinical trial design.43
With respect to inclusion criteria, targeting a single organ or
specific subgroup could lead to more definitive conclusions
regarding a study drug.51 The marked variability in disease
severity of enrolled participants could also impact the ability
to draw conclusions.52 For example, including participants
with low disease activity could introduce floor effects that
limit the ability to separate placebo from active treatment.
On the other hand, patients with the greatest need of novel
treatment approaches, namely with life threatening disease,53
are usually excluded from clinical trials. The impact of disease
duration and previous treatment on the study population
may also influence the effect of a study drug. The selected
outcome measures can substantially influence whether a clinical trial meets its intended endpoint. New potential outcome
measures have been proposed, such as the SLE-disease activity
score,54 intended as a continuous variable and the Lupus Low
Disease Activity State.55 Another outcome measure, LuMOS,
was developed from analysis of the belimumab trials and
shows superior ability to detect change compared with the
standard SRI-4.38 Other potentially novel outcome variables
for this heterogeneous disease might include hierarchical
outcomes. Using biomarkers either for inclusion or outcome
may solve issues surrounding disease heterogeneity.
Novel trial designs that could be used for SLE include adaptive designs currently used in oncology.56 Drug withdrawal
trials57 or trials that use flare for inclusion or outcome could also
be considered as they allow the participation of patients with
more severe disease. Novel designs might focus on reducing the
impact of placebo response, including placebo response related
to pretrial non-compliance.58 59 In considering targets of treatment, it is tempting to focus on autoimmune inflammatory
manifestations where exciting new discoveries provide novel
targets.60 However, it is essential to include patient-
focused
unmet needs.61 62 These include symptoms that impact quality of
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life such as pain, fatigue and cognitive dysfunction (‘lupus fog’)
which are typically resistant to immune-focused therapies. Treatments that could improve medication adherence, especially in
socially deprived populations and by approaches which require
less frequent dosing, or that can mitigate the important concern
of reproductive issues, are needed. Overall, there are abundant
opportunities for clinical scientists, pharmaceutical companies
and regulatory bodies to collaborate towards improved methodology to provide better patient outcomes.

Other systemic autoimmune rheumatic diseases
This group highlighted the unmet needs primarily within
systemic sclerosis this year, and similar to other groups, identified the issue of improving clinical trials of utmost importance.
Recent and current clinical trials have failed to demonstrate
efficacy for a variety of agents in the treatment of this disease,
although the results suggest that some disease manifestations
may actually be improved by certain agents.63 One difficulty
in designing clinical trials to date has been the heterogeneity
of disease manifestations. It might be appropriate to design
trials for a specific manifestation for example (eg, lung disease).
Alternatively an acceptable, sensitive, specific and quantitative
combined outcome measure that would be acceptable to regulatory agencies could speed the design and development of trials
for registration of new therapeutic agents.64 A dearth of predictive biomarkers also makes it difficult to target drug trials to
those with the greatest potential for benefit from specific therapeutic interventions.65 66 Finally, inclusion of patient-reported
outcomes of specific manifestations (eg, calcinosis) could allay
patients’ concerns about entering trials.67

Table 1 Identified unmet research needs of high priority within RA,
PSA, AxSpa, SLE and other systemic autoimmune rheumatic diseases
Rheumatoid arthritis

The need to better define treatment ‘refractory’ states both
phenotypically and molecularly
The need to focus on refractory patients in both the study
of novel targeted therapies and in the study of existing
therapies in novel combinations or sequences

Psoriatic arthritis

Understanding differential therapeutic effects on different
clinical domains in PsA such as enthesitis
Further evaluation of combination therapies and strategic
trials including the use of sequential therapies, controlled
withdrawal, the treatment of early disease and the
treatment of monoarticular or oligoarticular disease

Ankylosing
spondyloarthritis

Understanding the role of the microbiome in disease
pathogenesis and potential therapy
Understanding disease pathology specifically with regard to
why Il-23 inhibition does not improve the disease.

Systemic lupus
erythematosus

Improving clinical trial design by reducing heterogeneity
of participants, developing new outcome disease activity
measures, standardising serological testing and conducting
organ-specific trials
Consider alternative trial designs including adaptive trials
and withdrawal trials

Other systemic
Improving clinical trial design, specifically with reducing
autoimmune rheumatic heterogeneity in disease endotypes and the use of organ-
diseases
specific outcome measures
Identification of predictive biomarkers and the inclusion of
patient-reported outcomes of specific manifestations (eg,
calcinosis) for clinical trials
axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE,
systemic lupus erythematous.

Summary
The convening of the 21st ATT afforded the possibility to discuss
and articulate major unmet needs in the field of rheumatology,
and across domains there were several overarching perceived
unmet needs (table 1). It was generally understood that there has
not been sufficient emphasis on trial designs which concentrated
on well-defined disease subtypes. Many diseases have multiple
subtypes (eg, axial and peripheral PsA or limited/diffuse systemic
sclerosis with multiple serological subtypes) and trial designs
which mix those subtypes could obscure the success of treatments in specific subgroups. Likewise, trial designs which are
able to dissect (or include) overlapping diseases are also needed.
While there has been some success in treating moderate to
severe patients with various inflammatory rheumatic diseases
and even inclusion of some patients with Disease Modifying
anti-Rheumatic Drugs (DMARD)-refractory disease in RA, this
remains a top unmet need in RA that has been even less carefully
examined in patients with other diseases. For example, patients
with PsA are often included in trials only if they have been naïve
to previous conventional synthetic DMARD (csDMARDs) or
biologic DMARD (bDMARDs); more attention needs to be paid
to patients who are more ‘difficult-to-treat’ across all conditions,
as well as those who have multiple complications or comorbidities or those who have failed other csDMARDs or bDMARDs.
Last, while progress has been made in treating patients who
used to have unmet need within countries and regions such as
Australia, Japan, North America and the European Union, it was
highlighted that more emphasis needed to be placed on understanding unmet needs in other countries and continents such as
Africa, multiple areas in Asia and Central and South America.
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